Genzyme Corporation 

(Public, NASDAQ:GENZ)   Watch this stock   
Find more results for genzyme
Feb 17, 2010
Q4 2009 Earnings Release - 12:00PM EST - Add to calendar
Feb 17, 2010
Q4 2009 Earnings Conference Call - 11:00AM EST - Add to calendar
Nov 18, 2009
Lazard Capital Healthcare Conference
Nov 17, 2009
Genzyme/Isis Investor Event at American Heart Association Conference - Webcast
Nov 12, 2009
Credit Suisse Healthcare Conference
Oct 21, 2009
Q3 2009 Earnings Conference Call - Webcast
Oct 21, 2009
Q3 2009 Earnings Release
Sep 23, 2009
UBS Global Life Sciences Conference
Sep 15, 2009
Morgan Stanley Global Healthcare Conference - Webcast
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 1.51% 9.14%
Operating margin 1.14% 12.63%
EBITD margin - 20.77%
Return on average assets 0.64% 4.96%
Return on average equity 0.83% 6.05%
Employees 11,000 -

Address

500 Kendall Street
Cambridge, MA 02142
United States - Map
+1-617-2527500 (Phone)
+1-617-2527600 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Transcripts - SeekingAlpha

Genzyme Corporation discussions

  View all discussions »

Description

Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases and other chronic debilitating diseases, including a family of diseases known as lysosomal storage disorders (LSDs). Cardiometabolic and Renal segment develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure and endocrine and cardiovascular diseases. Biosurgery segment develops, manufactures and distributes biotherapeutics and biomaterial-based products, with a focus on products that meet medical needs in the orthopaedics and broader surgical areas. Hematologic Oncology segment develops, manufactures and distributes products for the treatment of cancer.

Officers and directors

Henri A. Termeer
Chairman of the Board, President, Chief Executive Officer
Age: 63
Bio & Compensation - Reuters
Michael S. Wyzga
Chief Financial Officer, Executive Vice President - Finance
Age: 54
Bio & Compensation - Reuters
Peter Wirth
Executive Vice President - Legal and Corporate Development, Secretary
Portrait. Age: 58
Bio & Compensation - Reuters
Earl M. Collier Jr.,Esq
Executive Vice President
Age: 61
Bio & Compensation - Reuters
Sandford D. Smith
Executive Vice President and President - International Group
Age: 61
Bio & Compensation - Reuters
David P. Meeker M.D.
Executive Vice President - Genetic Diseases, Biosurgery & Transplant
Age: 54
Bio & Compensation - Reuters
Alan E. Smith Ph.D.
Chief Scientific Officer, Senior Vice President - Research
Age: 63
Bio & Compensation - Reuters
Thomas J. DesRosier
Senior Vice President, General Counsel, Chief Legal Officer
Age: 54
Bio & Compensation - Reuters
Richard A. Moscicki M.D.
Senior Vice President - Biomedical & Regulatory Affairs, Chief Medical Officer
Age: 56
Bio & Compensation - Reuters
Zoltan A. Csimma
Senior Vice President and Chief Human Resources Officer
Age: 67
Bio & Compensation - Reuters